Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Matsuda T
Department of Internal Medicine (III), Kanazawa University School of Medicine, Japan.
Am J Hematol. 1991 Mar;36(3):176-83. doi: 10.1002/ajh.2830360304.
Plasma levels of tissue-plasminogen activator.plasminogen activator inhibitor (t-PA.PAI) complex and active PAI were assayed in 58 cases of disseminated intravascular coagulation (DIC). A significant elevation of both parameters was observed in most cases of DIC, especially in patients with non-Hodgkin lymphoma, sepsis, or some patients with acute leukemia, but no such elevation was observed in patients with acute promyelocytic leukemia (APL). The levels of both parameters were higher in cases of DIC with multiple organ failure (MOF) than in those without MOF. Since no elevation of t-PA.PAI complex was observed in most cases of APL, t-PA did not seem to play an important role in the activation of fibrinolytic system in APL. Active PAI, which reflects the inhibitory regulation in fibrinolytic system, was considered to play a role in the progression of MOF. Plasma levels of active PAI were low in the cases of APL, which had no complication of MOF.
对58例弥散性血管内凝血(DIC)患者检测了血浆组织型纤溶酶原激活物-纤溶酶原激活物抑制剂(t-PA.PAI)复合物和活性PAI水平。在大多数DIC病例中,观察到这两个参数均显著升高,尤其是在非霍奇金淋巴瘤、脓毒症患者或部分急性白血病患者中,但急性早幼粒细胞白血病(APL)患者未观察到此类升高。伴有多器官功能衰竭(MOF)的DIC病例中这两个参数的水平高于无MOF的病例。由于大多数APL病例未观察到t-PA.PAI复合物升高,t-PA似乎在APL纤溶系统激活中未发挥重要作用。反映纤溶系统抑制调节的活性PAI被认为在MOF进展中起作用。无MOF并发症的APL病例中活性PAI的血浆水平较低。